Express News | Replimune Presents Late-Breaking Abstract Featuring Data From Ignyte Clinical Trial of Rp1 Combined With Nivolumab in Anti-Pd1 Failed Melanoma at the 39TH Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

BreakingsNov 10 02:00

Press Release: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow JonesOct 10 04:01

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings

Yahoo FinanceOct 8 09:11

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Simply Wall StOct 2 21:31

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate

Yahoo FinanceOct 2 20:02

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswireOct 1 20:00